CRDF (Cardiff Oncology) Total Stockholders Equity: $26.53 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CRDF Cardiff Oncology Inc CRDF
31 GF Score
Price $1.03
! 5 Warning Signs
View Full Analysis

What is Cardiff Oncology Total Stockholders Equity?

Cardiff Oncology CRDF +3.51% 31 Total Stockholders Equity is $26.53 Mil as of Jun. 2026. GuruFocus rates CRDF with a GF Score™ of 31/100. The stock has 5 warning signs investors should review.

Cardiff Oncology's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $26.53 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Cardiff Oncology's Book Value per Share for the quarter that ended in Jun. 2026 was $0.39. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Cardiff Oncology's Debt-to-Equity for the quarter that ended in Jun. 2026 was 0.02.

Cardiff Oncology  (NAS:CRDF) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Cardiff Oncology's Book Value per Share for the quarter that ended in Jun. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(26.532-0)/68.502
=0.39

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Cardiff Oncology's Debt-to-Equity for the quarter that ended in Jun. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.457 + 0) / 26.532
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cardiff Oncology Total Stockholders Equity Related Terms

Cardiff Oncology Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Cardiff Oncology's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cardiff Oncology Total Stockholders Equity Chart

Cardiff Oncology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 140.42 106.34 69.74 82.95 45.39

Cardiff Oncology Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 58.61 48.79 45.39 34.71 26.53
CRDF
31GF Score
Cardiff Oncology Inc CRDF
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $26.53 Mil mean?
Cardiff Oncology (CRDF) has a Total Stockholders Equity of $26.53 Mil as of Jun. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Cardiff Oncology and its competitors.
Is Cardiff Oncology's Total Stockholders Equity too high?
Cardiff Oncology's current Total Stockholders Equity is $26.53 Mil. Overall, Cardiff Oncology has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Cardiff Oncology's Total Stockholders Equity compare to MNOV and PMVP?
Cardiff Oncology's Total Stockholders Equity of $26.53 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Cardiff Oncology and its competitors. Cardiff Oncology's current Total Stockholders Equity is $26.53 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiff Oncology stock overvalued right now?
Cardiff Oncology (CRDF) has a current Total Stockholders Equity of $26.53 Mil. The current Total Stockholders Equity is $26.53 Mil. Cardiff Oncology's overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Cardiff Oncology (CRDF), the current Total Stockholders Equity is $26.53 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cardiff Oncology Business Description

Other Exchanges XE7C:Germany
Address 11055 Flintkote Avenue, San Diego, CA, USA, 92121
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
31GF Score

Get the complete analysis for CRDF

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.03
Price